» Articles » PMID: 38325801

Magnetically Guided Surgery After Primary Systemic Therapy for Breast Cancer: Implications for Enhanced Axillary Mapping

Overview
Journal Br J Surg
Specialty General Surgery
Date 2024 Feb 7
PMID 38325801
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Superparamagnetic iron nanoparticles perform comparably to radioisotope ± blue dye for sentinel lymph node detection in breast cancer, even when injected up to 8 weeks before surgery. Using superparamagnetic iron nanoparticles for sentinel lymph node detection after primary systemic therapy, and the maximum time frame of superparamagnetic iron nanoparticle administration have not been investigated.

Methods: This cohort study included cN0/1-to-ycN0 patients undergoing sentinel lymph node detection or targeted axillary dissection. All patients received superparamagnetic iron nanoparticles either before primary systemic therapy or before surgery, and radioisotope on the day of surgery.

Results: For 113 patients analysed, superparamagnetic iron nanoparticles were injected a median of 3 (range 0-248) days before surgery, with a 97.4% detection rate compared with 91.2% for radioisotope (P = 0.057). Concordance for radioisotope was 97.1% and this was not affected by timing of superparamagnetic iron nanoparticle injection (Kendall's tau 0.027; P = 0.746). The median sentinel lymph node yield was 3 (interquartile range (i.q.r.) 2-3) for superparamagnetic iron nanoparticles and 2 (i.q.r. 2-3) for radioisotope (P < 0.001). In targeted axillary dissection, detection was 100% for superparamagnetic iron nanoparticles and 81.8% for radioisotope (P = 0.124). The index node was magnetic in 93.9% and radioactive in 66.7% (P = 0.007), an outcome that was not affected by any factors. For patients with metastases, superparamagnetic iron nanoparticle detection was 100% and radioisotope-based detection was 84.2% (P = 0.083), with superparamagnetic iron nanoparticles detecting more metastatic sentinel lymph nodes (median of 1 (i.q.r. 1-2) for superparamagnetic iron nanoparticles compared with a median of 1 (i.q.r. 0-1) for radioisotope; P = 0.005).

Conclusion: Injection before primary systemic therapy is feasible and does not affect concordance with radioisotope. Superparamagnetic iron nanoparticles perform comparably to radioisotope, but detect more sentinel lymph nodes and have a higher rate of detection of metastatic sentinel lymph nodes.

Citing Articles

Axillary surgical staging after neoadjuvant chemotherapy: does technical accuracy matter?.

Marin C, Gergelis K, Weiss A Gland Surg. 2024; 13(8):1353-1357.

PMID: 39282043 PMC: 11399019. DOI: 10.21037/gs-24-183.


The Use of Sentinel Lymph Node Biopsy in Patients Undergoing Mastectomy for DCIS.

Johnson M, Cortina C, Aldakkak M, Huang C, Kong A Clin Breast Cancer. 2024; 24(7):611-619.

PMID: 39127597 PMC: 11402566. DOI: 10.1016/j.clbc.2024.07.003.

References
1.
Boileau J, Poirier B, Basik M, Holloway C, Gaboury L, Sideris L . Sentinel node biopsy after neoadjuvant chemotherapy in biopsy-proven node-positive breast cancer: the SN FNAC study. J Clin Oncol. 2014; 33(3):258-64. DOI: 10.1200/JCO.2014.55.7827. View

2.
Caudle A, Yang W, Krishnamurthy S, Mittendorf E, Black D, Gilcrease M . Improved Axillary Evaluation Following Neoadjuvant Therapy for Patients With Node-Positive Breast Cancer Using Selective Evaluation of Clipped Nodes: Implementation of Targeted Axillary Dissection. J Clin Oncol. 2016; 34(10):1072-8. PMC: 4933133. DOI: 10.1200/JCO.2015.64.0094. View

3.
Mamounas E, Brown A, Anderson S, Smith R, Julian T, Miller B . Sentinel node biopsy after neoadjuvant chemotherapy in breast cancer: results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol. 2005; 23(12):2694-702. DOI: 10.1200/JCO.2005.05.188. View

4.
Reig B, Lewin A, Du L, Heacock L, Toth H, Heller S . Breast MRI for Evaluation of Response to Neoadjuvant Therapy. Radiographics. 2021; 41(3):665-679. DOI: 10.1148/rg.2021200134. View

5.
Caudle A, Bedrosian I, Milton D, DeSnyder S, Kuerer H, Hunt K . Use of Sentinel Lymph Node Dissection After Neoadjuvant Chemotherapy in Patients with Node-Positive Breast Cancer at Diagnosis: Practice Patterns of American Society of Breast Surgeons Members. Ann Surg Oncol. 2017; 24(10):2925-2934. PMC: 5759951. DOI: 10.1245/s10434-017-5958-4. View